QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PFE   39.99 (-0.57%)
PYPL   72.70 (-0.82%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PFE   39.99 (-0.57%)
PYPL   72.70 (-0.82%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PFE   39.99 (-0.57%)
PYPL   72.70 (-0.82%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PFE   39.99 (-0.57%)
PYPL   72.70 (-0.82%)
NFLX   323.52 (-1.26%)

Ocular Therapeutix - OCUL Stock Forecast, Price & News

$5.07
-0.07 (-1.36%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.94
$5.29
50-Day Range
$3.87
$6.27
52-Week Range
$2.57
$6.53
Volume
640,329 shs
Average Volume
1.52 million shs
Market Capitalization
$392.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50

Ocular Therapeutix MarketRank™ Forecast

Analyst Rating
Buy
3.33 Rating Score
Upside/​Downside
126.8% Upside
$11.50 Price Target
Short Interest
Bearish
5.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.01
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$161,777 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.03) to ($0.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

316th out of 1,002 stocks

Pharmaceutical Preparations Industry

136th out of 488 stocks


OCUL stock logo

About Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

OCUL Stock News Headlines

JMP Securities Keeps Their Buy Rating on Aura Biosciences Inc (AURA)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
A strange force is brewing…
An economic force with the potential to be bigger than the 1880s railroad boom, the 1920s automobile boom, the baby boom of the 1960s, or the Dotcom boom of the ‘90s. And while Biden has nothing to do with it… he’ll take full credit. pixel
Q4 2022 Ocular Therapeutix Inc Earnings Call
Why Shares of Ocular Therapeutix Jumped This Week
Berenberg Bank Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
Ocular Soars after Positive Interim Data
See More Headlines
Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

OCUL Company Calendar

Last Earnings
11/08/2021
Today
3/28/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCUL
Employees
228
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.50
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+126.8%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$-71,040,000.00
Net Margins
-137.95%
Pretax Margin
-137.95%

Debt

Sales & Book Value

Annual Sales
$51.49 million
Book Value
$0.46 per share

Miscellaneous

Free Float
73,789,000
Market Cap
$392.97 million
Optionable
Optionable
Beta
1.28

Key Executives

  • Antony MattessichAntony Mattessich
    President, Chief Executive Officer & Director
  • Donald Notman
    Chief Financial Officer
  • Peter Jarrett
    Chief Scientific Officer
  • Rabia Gurses Ozden
    Chief Medical Officer
  • Karen-Leigh Edwards
    Senior Vice President-Technical Operations













OCUL Stock - Frequently Asked Questions

Should I buy or sell Ocular Therapeutix stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCUL shares.
View OCUL analyst ratings
or view top-rated stocks.

What is Ocular Therapeutix's stock price forecast for 2023?

3 equities research analysts have issued 1-year price objectives for Ocular Therapeutix's shares. Their OCUL share price forecasts range from $10.00 to $14.00. On average, they expect the company's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 126.8% from the stock's current price.
View analysts price targets for OCUL
or view top-rated stocks among Wall Street analysts.

How have OCUL shares performed in 2023?

Ocular Therapeutix's stock was trading at $2.81 at the beginning of 2023. Since then, OCUL shares have increased by 80.4% and is now trading at $5.07.
View the best growth stocks for 2023 here
.

When is Ocular Therapeutix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our OCUL earnings forecast
.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.03. The biopharmaceutical company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.13 million. Ocular Therapeutix had a negative trailing twelve-month return on equity of 127.95% and a negative net margin of 137.95%. During the same quarter in the prior year, the company posted ($0.17) EPS.

What ETFs hold Ocular Therapeutix's stock?

ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include Invesco Raymond James SB-1 Equity ETF (RYJ), SPDR S&P Pharmaceuticals ETF (XPH), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Biotechnology ETF (IBBQ) and

What guidance has Ocular Therapeutix issued on next quarter's earnings?

Ocular Therapeutix updated its FY 2023 earnings guidance on Monday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $55.00 million-$60.00 million, compared to the consensus revenue estimate of $69.98 million.

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Summer Road LLC (7.95%), Opaleye Management Inc. (7.89%), Deltec Asset Management LLC (2.41%), Geode Capital Management LLC (1.83%), Emerald Advisers LLC (1.25%) and Emerald Mutual Fund Advisers Trust (0.88%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends
.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $5.07.

How much money does Ocular Therapeutix make?

Ocular Therapeutix (NASDAQ:OCUL) has a market capitalization of $392.97 million and generates $51.49 million in revenue each year. The biopharmaceutical company earns $-71,040,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

How many employees does Ocular Therapeutix have?

The company employs 228 workers across the globe.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The official website for the company is www.ocutx.com. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at chris.brinzey@westwicke.com, or via fax at 781-357-4001.

This page (NASDAQ:OCUL) was last updated on 3/28/2023 by MarketBeat.com Staff